Press Releases Year: - Any -2021202020192018 Items per page 102550 November 19, 2020 at 6:30 AM EST Summary ToggleEntera Bio Ltd Announces Third Quarter 2020 Financial Results and Provides Clinical Update ‒ Completed E nrollment in Phase 2 Clinical Trial of EB613, P ositioned as the F irst P otential O ral B one B uilding P roduct to T reat O steoporosis ‒ ‒ Positive Interim 6-Month Bone Mineral Density ( BMD ) Data Reported in Phase 2 EB613 Clinical Trial ‒ ‒ Company Expect s to Report Bio m arker November 13, 2020 at 7:30 AM EST Summary ToggleEntera Bio to Report Third Quarter 2020 Business and Financial Results on November 19, 2020 BOSTON JERUSALEM, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended September 30, 2020 on November 19, 2020, before the U.S. November 9, 2020 at 8:30 AM EST Summary ToggleEntera Bio Ltd Announces Completion of Enrollment In Phase 2 Clinical Trial of Eb613 In Osteoporosis ‒ Company Expect s to Report Interim 3 Month Bio m arker Data for All Enrolled Patients in Q1:21 with Final Bone Mineral Density, or BMD, Data Expected in Q2:21 ‒ ‒ Results Expected Are Expected to Inform the Design of Potential Global Phase 3 Clinical Trial ‒ BOSTON and JERUSALEM, Israel, Nov. November 2, 2020 at 4:05 PM EST Summary ToggleEntera Bio to Present at the H.C. Wainwright 6th Annual Israel Conference BOSTON and JERUSALEM, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will host a virtual presentation at the H.C. September 10, 2020 at 8:30 AM EDT Summary ToggleEntera Bio to Present at the H.C. Wainwright 22nd Annual Global Investment Conference BOSTON and JERUSALEM, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate virtually in the H.C. Wainwright Global Investment Conference August 20, 2020 at 6:30 AM EDT Summary ToggleEntera Bio Ltd Announces Interim Data From Phase 2 Clinical Trial of EB613 in Osteoporosis and Second Quarter 2020 Financial Results ‒ 6-Month Interim Data Indicate EB 613 Has Meaningful and Positive Impact on Lumbar Spine Bone Mineral Density (BMD) in a Dose Dependent Manner – ‒ Company Expects to Complete Patient Enrollment in Q3:20 and Report Interim Biomarker Data from 2.5 mg Dose in Q1:21 with Final Data Expected in Q2:21 August 17, 2020 at 8:30 AM EDT Summary ToggleEntera Bio to Report Second Quarter 2020 Business and Financial Results on August 20, 2020 BOSTON and JERUSALEM, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended June 30, 2020 on August 20, 2020, before the U.S. August 10, 2020 at 8:30 AM EDT Summary ToggleEntera Bio Announces Management Changes BOSTON and JERUSALEM, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that its Board of Directors has appointed Roger Garceau as Interim Chief Executive Officer, effective immediately. August 5, 2020 at 8:30 AM EDT Summary ToggleEntera Bio to Present at BTIG’s Virtual Biotechnology Conference BOSTON and JERUSALEM, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate virtually in the BTIG Biotechnology Conference on Monday, August 10, July 22, 2020 at 4:05 PM EDT Summary ToggleEntera Bio Ltd. Announces Highly Encouraging Oral PTH Market Survey Results ‒ Approximately 85% of Clinicians Surveyed Likely to Prescribe Oral Parathyroid Hormone (PTH) to Treat Moderate to Severe Osteoporosis ‒ ‒ Oral PTH Described by Clinicians as Potential Game-Changer that Addresses Substantial Unmet Need with Possibility of Improving Patient Compliance and Comfort ‒ Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last